Previous 10 | Next 10 |
SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announ...
La Jolla Pharmaceutical (NASDAQ: LJPC ): Q3 GAAP EPS of -$1.08 misses by $0.02 . More news on: La Jolla Pharmaceutical Company, Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today ann...
Gainers: Tiffany & Co. (NYSE: TIF ) +31% . Xunlei Limited (NASDAQ: XNET ) +27% . Datasea (NASDAQ: DTSS ) +25% . comScore (NASDAQ: SCOR ) +24% . Fitbit (NYSE: FIT ) +23% . Aquestive Therapeutics (NASDAQ: AQST ) +23% . ChinaNet Online Holdings (NASDAQ: CNET ) +20% . Libbey (...
SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today annou...
The European Commision approves La Jolla Pharmaceutical Company's (NASDAQ: LJPC ) GIAPREZA (angiotensin II) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholam...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 119 weeks of public selections as part of this ongoing live forward-testing. In...
La Jolla Pharmaceutical (NASDAQ: LJPC ): Q2 GAAP EPS of -$1.12 misses by $0.01 . More news on: La Jolla Pharmaceutical Company, Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announ...
-Orphan Drug Designation Program offers potentially up to seven years of marketing exclusivity- -NDA Submission Planned for Fourth Quarter of 2019- SAN DIEGO, July 23, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, developme...
News, Short Squeeze, Breakout and More Instantly...
La Jolla Pharmaceutical Company Company Name:
LJPC Stock Symbol:
NASDAQ Market:
La Jolla Pharmaceutical Company Website:
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of L...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...